339 related articles for article (PubMed ID: 30710758)
1. Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction.
Böttger F; Schaaij-Visser TB; de Reus I; Piersma SR; Pham TV; Nagel R; Brakenhoff RH; Thunnissen E; Smit EF; Jimenez CR
J Proteomics; 2019 Mar; 196():106-119. PubMed ID: 30710758
[TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling.
de Wit M; Kant H; Piersma SR; Pham TV; Mongera S; van Berkel MP; Boven E; Pontén F; Meijer GA; Jimenez CR; Fijneman RJ
J Proteomics; 2014 Mar; 99():26-39. PubMed ID: 24418523
[TBL] [Abstract][Full Text] [Related]
3. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer.
Hu R; Huffman KE; Chu M; Zhang Y; Minna JD; Yu Y
J Proteome Res; 2016 Feb; 15(2):477-86. PubMed ID: 26736068
[TBL] [Abstract][Full Text] [Related]
5. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context.
Schaaij-Visser TB; de Wit M; Lam SW; Jiménez CR
Biochim Biophys Acta; 2013 Nov; 1834(11):2242-58. PubMed ID: 23376433
[TBL] [Abstract][Full Text] [Related]
6. SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
Bell EH; Chakraborty AR; Mo X; Liu Z; Shilo K; Kirste S; Stegmaier P; McNulty M; Karachaliou N; Rosell R; Bepler G; Carbone DP; Chakravarti A
Clin Cancer Res; 2016 May; 22(10):2396-404. PubMed ID: 26671993
[TBL] [Abstract][Full Text] [Related]
7. Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits.
Wu Z; Liu Z; Jiang X; Mi Z; Meng M; Wang H; Zhao J; Zheng B; Yuan Z
J Exp Clin Cancer Res; 2019 Aug; 38(1):341. PubMed ID: 31387622
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-mass secretome profiling identifies C-C motif chemokine 5 as a potential plasma biomarker and therapeutic target for nasopharyngeal carcinoma.
Lin SJ; Chang KP; Hsu CW; Chi LM; Chien KY; Liang Y; Tsai MH; Lin YT; Yu JS
J Proteomics; 2013 Dec; 94():186-201. PubMed ID: 24080422
[TBL] [Abstract][Full Text] [Related]
9. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas.
Wu CC; Hsu CW; Chen CD; Yu CJ; Chang KP; Tai DI; Liu HP; Su WH; Chang YS; Yu JS
Mol Cell Proteomics; 2010 Jun; 9(6):1100-17. PubMed ID: 20124221
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Ota S; Ishii G; Goto K; Kubota K; Kim YH; Kojika M; Murata Y; Yamazaki M; Nishiwaki Y; Eguchi K; Ochiai A
Lung Cancer; 2009 Apr; 64(1):98-104. PubMed ID: 18823676
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
[TBL] [Abstract][Full Text] [Related]
12. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines.
Planque C; Kulasingam V; Smith CR; Reckamp K; Goodglick L; Diamandis EP
Mol Cell Proteomics; 2009 Dec; 8(12):2746-58. PubMed ID: 19776420
[TBL] [Abstract][Full Text] [Related]
13. TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells.
Mohammed Ael S; Eguchi H; Wada S; Koyama N; Shimizu M; Otani K; Ohtaki M; Tanimoto K; Hiyama K; Gaber MS; Nishiyama M
Exp Lung Res; 2012 Nov; 38(9-10):463-74. PubMed ID: 23098063
[TBL] [Abstract][Full Text] [Related]
14. RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.
Tessari A; Parbhoo K; Pawlikowski M; Fassan M; Rulli E; Foray C; Fabbri A; Embrione V; Ganzinelli M; Capece M; Campbell MJ; Broggini M; La Perle K; Farina G; Cole S; Marabese M; Hernandez M; Amann JM; Pruneri G; Carbone DP; Garassino MC; Croce CM; Palmieri D; Coppola V
Oncogene; 2018 Dec; 37(50):6463-6476. PubMed ID: 30076413
[TBL] [Abstract][Full Text] [Related]
15. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
16. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
17. Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
Buhl IK; Santoni-Rugiu E; Ravn J; Hansen A; Christensen IJ; Jensen T; Pratt B; Askaa J; Jensen PB; Knudsen S; Sørensen JB
PLoS One; 2018; 13(3):e0194609. PubMed ID: 29566065
[TBL] [Abstract][Full Text] [Related]
18. Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway.
Mei Y; Liu YB; Hu DL; Zhou HH
Int J Biol Sci; 2018; 14(13):1859-1872. PubMed ID: 30443189
[TBL] [Abstract][Full Text] [Related]
19. SWATH™- and iTRAQ-based quantitative proteomic analyses reveal an overexpression and biological relevance of CD109 in advanced NSCLC.
Zhang F; Lin H; Gu A; Li J; Liu L; Yu T; Cui Y; Deng W; Yan M; Li J; Yao M
J Proteomics; 2014 May; 102():125-36. PubMed ID: 24667143
[TBL] [Abstract][Full Text] [Related]
20. Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.
Lin TC; Tsai LH; Chou MC; Chen CY; Lee H
Tumour Biol; 2016 Mar; 37(3):4017-23. PubMed ID: 26482622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
